Genmab — Maj 2020
-
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody
Platform against a Pair of Disease Relevant Targets https://www.prnewswire.com/news-releases/tavotek-announces-a-research-agreement-with-genmab-for-the-development-of-bispecific-antibodies-using-genmabs-duobody-platform-against-a-pair-of-disease-relevant-targets-301064163.html -
UBS increase target on Genmab to 2500 from 1460, and view to buy from neutral

-
Er du da svedt.

-
Except for ofa and EnaV, UBS add value to the whole product pipeline from Genmab
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
